Publication Citing Use of Biochempartner Products

Novel-smoothened inhibitors for therapeutic targeting of naïve and drug-resistant hedgehog pathway-driven cancers

Publications Citing of Biochempartner's Vismodegib(CAS:879085-55-9)

The TSC1‐mTOR‐PLK axis regulates the homeostatic switch from Schwann cell proliferation to myelination in a stage‐specific manner

Publications Citing of Biochempartner's BI 2536(CAS:755038-02-9)

Conjugate Polyplexes with Anti-Invasive Properties and Improved siRNA Delivery In Vivo

Publications Citing of Biochempartner's Plerixafor(CAS:110078-46-1)

Suppression of glioblastoma by a drug cocktail reprogramming tumor cells into neuronal like cells

Publications Citing of Biochempartner's Fasudil(CAS:103745-39-7);Fasudil hydrochloride(CAS:105628-07-7);D-Luciferin(CAS:2591-17-5);Temozolomide(CAS:85622-93-1)

In Vitro Activity of Clofazimine against Nontuberculous Mycobacteria Isolated in Beijing, China

Publications Citing of Biochempartner's Bedaquiline(CAS:843663-66-1)

In vivo acquired sorafenib-resistant patient-derived tumor model displays alternative angiogenic pathways, multi-drug resistance and chromosome instability

Publications Citing of Biochempartner's AZD4547(CAS:1035270-39-3)

CXCR4-targeted liposomal mediated co-delivery of pirfenidone and AMD3100 for the treatment of TGFβ-induced HSC-T6 cells activation

Publications Citing of Biochempartner's Plerixafor(CAS:110078-46-1)

Inhibition of SGK1 confers vulnerability to redox dysregulation in cervical cancer

Publications Citing of Biochempartner's GSK 650394(CAS:890842-28-1)

Involvement of Vasopressin in the Pathogenesis of Pulmonary Tuberculosis: A New Therapeutic Target?

Publications Citing of Biochempartner's Conivaptan(CAS:210101-16-9)

In Vitro Activities of Bedaquiline and Delamanid against Nontuberculous Mycobacteria Isolated in Beijing, China

Publications Citing of Biochempartner's Delamanid(CAS:681492-22-8)

Increased Survival by Pulmonary Treatment of Established Lung Metastases with Dual STAT3/CXCR4 Inhibition by siRNA Nanoemulsions

Publications Citing of Biochempartner's Plerixafor(CAS:110078-46-1)

Gemcitabine-loaded RGD modified liposome for ovarian cancer: preparation, characterization and pharmacodynamic studies

Publications Citing of Biochempartner's RGD (Arg-Gly-Asp) Peptides(CAS:99896-85-2)

Silencing KIF14 reverses acquired resistance to sorafenib in hepatocellular carcinoma

Publications Citing of Biochempartner's MK-2206(CAS:1032349-93-1)

The iron chelator Deferasirox causes severe mitochondrial swelling without depolarization due to a specific effect on inner membrane permeability

Publications Citing of Biochempartner's Deferasirox(CAS:201530-41-8)

SIRT1 inhibits chemoresistance and cancer stemness of gastric cancer by initiating an AMPK/FOXO3 positive feedback loop

Publications Citing of Biochempartner's AS1842856(CAS:836620-48-5)

PCC0208025 (BMS202), a small molecule inhibitor of PD-L1, produces an antitumor effect in B16-F10 melanoma-bearing mice

Publications Citing of Biochempartner's BMS-202(CAS:1675203-84-5)

Piceatannol Suppresses the Proliferation and Induced Apoptosis of Osteosarcoma Cells Through PI3K/AKT/mTOR Pathway

Publications Citing of Biochempartner's 740Y-P(CAS:1236188-16-1)

Targeting pulmonary tumor microenvironment with CXCR4-inhibiting nanocomplex to enhance anti–PD-L1 immunotherapy

Publications Citing of Biochempartner's Plerixafor(CAS:110078-46-1)

Experimental Treatment of Mucinous Peritoneal Metastases Using Patient-Derived Xenograft Models

Publications Citing of Biochempartner's Cabazitaxel(CAS:183133-96-2)

s-HBEGF/SIRT1 circuit-dictated crosstalk between vascular endothelial cells and keratinocytes mediates sorafenib-induced hand–foot skin reaction that can be reversed by nicotinamide

Publications Citing of Biochempartner's Sorafenib(CAS:284461-73-0)

About BioChemPartner

Customer Support

Ordering

Contact BioChemPartner